Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer’s Disease
BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and Alzheimer’s disease (AD)conditions, and a subsidiary of Beyond Air (NASDAQ: XAIR), is proud to announce the appointment of Nobel Prize laureate, Professor Dan Shechtman, to its Scientific Advisory Board (SAB).
“We are delighted to welcome Professor Shechtman to our Scientific Advisory Board,” said Amir Avniel, CEO of NeuroNOS. “The addition of Professor Shechtman, alongside Professor Roger Kornberg from Stanford University, brings unparalleled scientific expertise to our team. Having two Nobel Prize laureates guiding the NeuroNOS research team significantly enhances our capabilities and underscores our commitment to pioneering treatments for complex neurological disorders.”
NeuroNOS stands among a select group of biopharmaceutical companies exclusively dedicated to addressing complex brain disorders. The company’s proprietary platform uniquely integrates multidisciplinary tools - including high-end behavioral techniques, advanced AI, and specialized wet lab capabilities - to accelerate the development of treatments for challenging neurological disorders, such as ASD and AD. Recent preclinical studies have demonstrated the effectiveness of the NeuroNOS platform, reinforcing the company’s confidence in the potential of its platform to transform therapeutic approaches in neuropsychiatry and neurodegenerative diseases. Currently, the company is executing a series of key preclinical studies designed to support a planned IND application to the FDA. The company’s program remains on track to initiate first-in-human clinical trials for ASD in the United States in 2026. This will mark an exciting step forward in the company’s mission to transform treatment for individuals and families affected by these challenging conditions.
Professor Shechtman, who was awarded the 2011 Nobel Prize in Chemistry for his groundbreaking discovery of quasicrystals, brings decades of expertise in advanced materials science, structural chemistry, and innovation. Professor Shechtman is currently a Distinguished Professor at the Technion – Israel Institute of Technology and a globally recognized leader in materials science and crystallography. His discovery of quasicrystals revolutionized the field and challenged long-standing paradigms. Beyond his scientific achievements, Professor Shechtman is a passionate advocate for science education and innovation.
Professor Shechtman expressed his enthusiasm for joining the company’s SAB, “Science holds the key to addressing humanity’s greatest challenges. I am excited to collaborate with NeuroNOS and its team of world-class scientists to develop transformative therapies for Autism and Alzheimer’s disorders that impact millions worldwide.”
“As a Nobel Prize laureate and renowned scientist, Professor Shechtman's invaluable expertise will significantly elevate the scientific rigor at NeuroNOS. His guidance will play a pivotal role in advancing our efforts to develop the first effective treatment for the core symptoms of ASD,” said Prof. Haitham Amal, CSO of NeuroNOS, Associate Professor at The Hebrew University of Jerusalem, and Visiting Professor at Harvard Medical School. “This appointment comes at a pivotal time, as we advance our lead drug candidate BA-102 through preclinical and clinical development. The addition of Professor Shechtman’s expertise is expected to help accelerate the translation of cutting-edge science into impactful treatments.”
About NeuroNOS
NeuroNOS is at the forefront of developing innovative treatments for neurodevelopmental and neurodegenerative disorders. The company specializes in creating therapies based on small molecules that cross the blood-brain barrier to regulate Nitric Oxide (NO) levels in the brain. Preclinical studies conducted by NeuroNOS have demonstrated that NO is present at elevated levels in children with Autism Spectrum Disorder (ASD) and adults suffering from brain-related diseases such as Alzheimer’s and brain cancers. The company’s research has shown that managing NO levels in the brain is crucial for maintaining normal brain function. By leveraging this groundbreaking science, NeuroNOS aims to bring transformative therapies to those affected by these challenging conditions, ultimately improving individuals' lives. Through collaborations with leading research institutions and experts in the field, the company is committed to advancing medical innovation and delivering life-changing treatments.
Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous Nitric Oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections, such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. Also, the Company has partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of Autism Spectrum Disorder (ASD) and other neurological disorders. In addition, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
Forward Looking Statements
This press release contains “forward-looking statements” (as defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended). You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including those related to the completion of the offering, risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air undertakes no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
